United Therapeutics (UTHR) Wells Fargo 21st Annual Healthcare Conference summary

Strong intellectual property protection extends into the 2040s, supporting long-term exclusivity for key products. Accelerated share repurchase of $500 million brings total recent repurchases to $4 billion, reflecting confidence in future growth and undervaluation relative to market cap. The addressable patient population across PH-COPD, pulmonary fibrosis, and pulmonary hypertension is estimated at one million, with a projected 50% capture rate. Key near-term events include NDA submissions and PDUFA dates for nebulized Tyvaso in IPF and Gen RAL-DPI for pulmonary hypertension, with the latter expected to receive FDA approval by June next year. Fourteen new products are being rolled out over the next few years, targeting a cumulative annual pharma revenue of $50–100 billion, with multiple launches planned each year. Gen RAL-DPI is positioned as the only product to show clinical improvement in PH, with a once-daily pill format expected to shift prescribing patterns. Triple Gen RAL-DPI, combining three mechanisms of action in one pill, is expected to capture over 80% of PH patients by decade's end, with regulatory filings planned within 12–24 months after Gen RAL-DPI approval. The soft mist inhaler (Tresmi) for treprostinil is anticipated to drive growth in the inhalable franchise, with plans for rapid expansion into ILD, IPF, and PPF markets. The company follows an "approve and then improve" algorithm, sequentially advancing products through regulatory pathways and device innovations.